New Delhi : Glenmark launches Covid Drug Glenmark Pharmaceuticals has introduced the antiviral drug Favipiravir under the brand name Fabiflu to treat patients with mild to moderate Covid-19. The company gave this information on Saturday. The Mumbai-based company said on Friday that it had received permission from the Drug Controller General of India (DGCI) to manufacture and market the drug.
The company said Fibiflu is a favipiviriv drug for the treatment of Covid-19, which has been approved. Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said, “This approval has come at a time when corona virus cases in India are increasing more rapidly than before.” This has put our healthcare system under great pressure. He hoped that the availability of effective treatment like Fabiflu would help reduce this pressure to a great extent.
Saldanha said that in clinical trials Fabiflu showed fairly good results on patients suffering from mild infection of the corona virus. He said that apart from this it is a food drug which is a convenient option of treatment. He said that the company will work closely with the government and the medical community to make this drug easily available to patients across the country. This medicine will be available at the price of Rs 103 per tablet on the advice of a doctor.
On the first day, two doses of 1800 mg have to be taken. After that, two doses of 800 mg will have to be taken for 14 days. Glenmark Pharma said that patients with minor infections who are suffering from diabetes or heart disease can also be given this medicine. According to the Health Ministry, a record 14,516 cases of corona virus were reported in the country on Saturday. Now the number of people infected by this epidemic in the country has increased to 3,95,048. The epidemic has killed 12,948 people so far.